标题:First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
作者:Wang, Shuyun; Gao, Aiqin; Liu, Jie; Sun, Yuping
作者机构:[Wang, Shuyun; Gao, Aiqin; Liu, Jie; Sun, Yuping] Shandong Univ, Jinan Cent Hosp, Dept Oncol, 105 Jiefang Rd, Jinan, Shandong, Peoples R China.
通讯作者:Sun, YP
通讯作者地址:[Sun, YP]Shandong Univ, Jinan Cent Hosp, Dept Oncol, 105 Jiefang Rd, Jinan, Shandong, Peoples R China.
来源:CANCER CHEMOTHERAPY AND PHARMACOLOGY
出版年:2018
卷:81
期:3
页码:443-453
DOI:10.1007/s00280-017-3516-1
关键词:Activating EGFR mutation; NSCLC; EGFR-TKIs; Cytotoxic chemotherapy;; First-line treatment
摘要:As the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation, EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have significantly improved the median progression-free survival (PFS) up to 18.9 months. However, almost all patients eventually develop acquired resistance to EGFR-TKIs, which limits the first-line PFS. To overcome the resistance and improve overall survival, researchers have tried to identify the resistance mechanisms and develop new treatment strategies, among which a combination of EGFR-TKIs and cytotoxic chemotherapy is one of the hotspots. The data from preclinical and clinical studies on combined EGFR-TKIs and chemotherapy have shown very interesting results. Here, we reviewed the available preclinical and clinical studies on first-line EGFR-TKIs-chemotherapy combination in patients with advanced NSCLC harboring activating EGFR mutation, aiming to provide evidences for more potential choices and shed light on clinical treatment.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040377402&doi=10.1007%2fs00280-017-3516-1&partnerID=40&md5=9ba95da1c6ea5ba760da75296cbc60bc
TOP